$3,340,000 of JOHNSON & JOHNSON SERVICES INC lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"- Issues related to the SUPPORT Act Issues related to - artificial intelligence - data privacy - cybersecurity - robotics Issues related to - OECD proposals on global tax & implementation and/or related Presidential executive orders - corporate tax provisions in TCJA including in 2025 reconciliation bills - Issues related to Veterans Administration and Veterans Health Administration procurement and contracting processes for medical technology - H.R. 1539, Medical Device Electronic Labeling Act, regarding all provisions - H.R. XXXX/ S. 266, the Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, regarding all provisions - H.R. 946 ORPHAN Cures Act, regarding all provisions - S.864, H.R. XXX HELP Copays Act, regarding all provisions - H.R. 2214/ S. XXXX Delinking Revenue from Unfair Gouging (DRUG) Act, regarding all provisions - H.R. 1492/S. 832, Ensuring Pathways to Innovative Cures (EPIC) Act - PL117-169 The Inflation Reduction Act, regarding all provisions related to drug pricing and implementation Issues related to - direct to consumer advertising - clinical trial modernization - biosimilars - cardiovascular health - 340B - Heart Recovery Awareness Day & H.Res. 1301, designating February 20th Heart Recovery Awareness Day - Issues related to stroke care - S. 1040, Drug Competition Enhancement Act, regarding all provisions - S. 1041, Affordable Prescriptions for Patients Act of 2025, regarding all provisions - S. 1097, Interagency Patent Coordination and Improvement Act of 2025, regarding all provisions Issues related to - intellectual property, including S. 1040, a bill to amend the Federal Trade Commission Act to prohibit product hopping - Medication Affordability and Patent Integrity Act - patent thickets Issues related to - H.R. 1109, the Litigation Transparency Act of 2025, and transparency in domestic third-party litigation funding - the Protecting Our Courts from Foreign Manipulation Act, and transparency in foreign third-party litigation funding"
You can find more data on corporate lobbying on Quiver Quantitative.
JNJ Congressional Stock Trading
Members of Congress have traded $JNJ stock 23 times in the past 6 months. Of those trades, 19 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 1 purchase worth up to $50,000 on 03/31 and 1 sale worth up to $15,000 on 01/24.
- REPRESENTATIVE JOSH GOTTHEIMER has traded it 7 times. They made 6 purchases worth up to $90,000 on 01/24, 01/21, 01/16, 12/12, 11/26, 11/22 and 1 sale worth up to $15,000 on 03/07.
- REPRESENTATIVE JEFFERSON SHREVE has traded it 2 times. They made 2 purchases worth up to $100,000 on 03/05, 02/24 and 0 sales.
- REPRESENTATIVE LLOYD DOGGETT has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/04, 12/10 and 0 sales.
- REPRESENTATIVE BRUCE WESTERMAN purchased up to $15,000 on 03/03.
- REPRESENTATIVE MARJORIE TAYLOR GREENE has traded it 5 times. They made 5 purchases worth up to $75,000 on 01/08, 12/24, 11/25 and 0 sales.
- REPRESENTATIVE KEVIN HERN sold up to $250,000 on 12/31.
- REPRESENTATIVE VIRGINIA FOXX purchased up to $15,000 on 12/06.
- REPRESENTATIVE JARED MOSKOWITZ purchased up to $15,000 on 11/08.
- SENATOR TOMMY TUBERVILLE sold up to $50,000 on 10/29.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
JNJ Insider Trading Activity
JNJ insiders have traded $JNJ stock on the open market 4 times in the past 6 months. Of those trades, 1 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $JNJ stock by insiders over the last 6 months:
- JOSEPH J WOLK (Exec VP, CFO) sold 13,015 shares for an estimated $2,002,878
- ROBERT J DECKER (VP Corporate Controller) sold 6,999 shares for an estimated $1,160,994
- MARK A WEINBERGER purchased 1,000 shares for an estimated $147,220
- TIMOTHY SCHMID (EVP, WW Chair, MedTech) sold 403 shares for an estimated $62,928
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
JNJ Hedge Fund Activity
We have seen 1,535 institutional investors add shares of JNJ stock to their portfolio, and 2,052 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ removed 8,877,281 shares (-35.3%) from their portfolio in Q4 2024, for an estimated $1,283,832,378
- JPMORGAN CHASE & CO added 4,985,149 shares (+14.7%) to their portfolio in Q4 2024, for an estimated $720,952,248
- PINNACLE ASSOCIATES LTD added 4,703,577 shares (+359.8%) to their portfolio in Q4 2024, for an estimated $680,231,305
- LEGAL & GENERAL GROUP PLC removed 4,603,436 shares (-19.9%) from their portfolio in Q4 2024, for an estimated $665,748,914
- JANUS HENDERSON GROUP PLC added 4,559,147 shares (+134.5%) to their portfolio in Q4 2024, for an estimated $659,343,839
- LAZARD ASSET MANAGEMENT LLC removed 3,705,273 shares (-85.3%) from their portfolio in Q4 2024, for an estimated $535,856,581
- NORTHERN TRUST CORP added 3,363,235 shares (+12.3%) to their portfolio in Q4 2024, for an estimated $486,391,045
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
JNJ Analyst Ratings
Wall Street analysts have issued reports on $JNJ in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Raymond James issued a "Outperform" rating on 04/16/2025
- Citigroup issued a "Buy" rating on 01/22/2025
To track analyst ratings and price targets for JNJ, check out Quiver Quantitative's $JNJ forecast page.
JNJ Price Targets
Multiple analysts have issued price targets for $JNJ recently. We have seen 2 analysts offer price targets for $JNJ in the last 6 months, with a median target of $164.0.
Here are some recent targets:
- Jayson Bedford from Raymond James set a target price of $162.0 on 04/14/2025
- Vamil Divan from Guggenheim set a target price of $166.0 on 02/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
